The Harm Reduction Rollback: How SAMHSA’s New Directives Are Cutting Off Xylazine Wound Care

When a person who uses drugs develops a xylazine wound, it does not look like a typical injection site complication. The lesions appear at locations far from where the drug entered the body — the chest, back, arms — and they can progress rapidly, resisting standard wound care protocols in ways that leave many emergency department clinicians unprepared. Until recently, the community organizations equipped to respond were receiving federal funding to provide testing supplies, wound care kits, and on-site treatment education. That federal support is now gone.

On April 24, 2026, the Substance Abuse and Mental Health Services Administration sent Dear Colleague letters to its grantees signaling what STAT News described as “a clear shift away from harm reduction and practices that facilitate illicit drug use.” The letters explicitly banned federal funds for xylazine and medetomidine test strips, sterile syringes, fentanyl test strips, and overdose hotlines capable of remote emergency response coordination. The agency simultaneously cancelled approximately $1.7 billion in block grant funding and cut $350 million from overdose prevention programs, while reducing its own staff from roughly 900 to fewer than 450.

What Xylazine Does to the Body — and Why It Requires Specialized Response

Xylazine is a veterinary sedative that began appearing in the illicit drug supply as an adulterant in fentanyl-based products across multiple states. Unlike opioids, xylazine is not reversed by naloxone, meaning overdose response requires additional steps and longer observation windows. People may regain consciousness after naloxone administration but remain deeply sedated by the xylazine component.

The wounds xylazine causes are its most clinically distinctive feature. Unlike abscesses that form at injection sites, xylazine-associated skin ulcers appear systemically — sometimes developing at locations with no direct contact with the drug. They progress through layers of skin and soft tissue, require specialized debridement, and carry a risk of necrosis and secondary infection that can lead to amputation if untreated. Emergency departments that encounter these wounds without awareness of the xylazine connection often apply standard wound protocols that prove inadequate.

Community harm reduction organizations — the same organizations whose federal funding was just stripped — were at the front line of identifying these wounds, linking people to appropriate wound care, and providing test strips that allowed people to know xylazine was in their supply before using.

The Policy Gap: Congress Stalled While the Drug Spread

The legislative response to xylazine has been fragmented and slow. S.545, the Combating Illicit Xylazine Act, remains stalled in the 119th Congress. An analysis by The Regulatory Review published April 25 documented how Congress’s failure to act created a governance vacuum that has allowed xylazine to spread through drug supplies in more states with limited coordinated public health response.

The DEA has warned about xylazine since 2022. The Philadelphia region, where xylazine was dubbed “tranq dope,” experienced widespread contamination well before federal policy caught up. By the time SAMHSA’s April 24 letters arrived, xylazine had been documented in illicit supplies in more than 40 states.

The April 24 letters did not specifically target xylazine — they targeted the whole category of harm reduction supplies. But xylazine was explicitly named in the funding ban, alongside fentanyl and medetomidine. The practical effect: organizations that had been providing xylazine test strips and wound care training lost the federal funding mechanism that supported those programs.

What Remains Permissible — and What That Means in Practice

SAMHSA’s letters were careful to preserve certain activities. Naloxone distribution remained permissible. Sharps disposal kits retained federal funding eligibility. HIV and hepatitis testing continued to qualify. Professional use of test strips by law enforcement and medical workers was carved out.

The practical significance of this distinction: naloxone addresses opioid overdose. It does not address xylazine sedation. Sharps disposal prevents disease transmission but does not help a person know what adulterants are in their next dose. The supplies that were cut — test strips for xylazine and fentanyl, wound care materials, low-threshold syringe services — were the tools that specifically addressed the current complexity of the drug supply.

Sharps disposal prevents disease transmission but does not help a person know what adulterants are in their next dose.

The American Society of Addiction Medicine responded through its president, Dr. Stephen Taylor, stating the organization is “continuing to carefully review” the letters and will “engage with federal partners to ensure that national policies reflect evidence-based practices.” The letters are also being scrutinized for their implication that medication-assisted treatment with methadone and buprenorphine should not be a “default sentence to life-long medication use,” a framing that contradicts clinical guidelines ASAM has spent years building consensus around.

Why This Matters for People in Recovery

The people most affected by these policy changes are people who are actively using — often people who are not yet in, or not yet ready for, formal treatment. Harm reduction operates on a principle that keeping people alive and reducing their physical harm during active use creates more opportunities for eventual recovery, not fewer. The data have consistently supported this: syringe services programs reduce HIV and hepatitis C transmission without increasing drug use; naloxone distribution saves lives; fentanyl test strips reduce overdose deaths among the people who use them.

Xylazine wound care is an extension of this logic. A person whose wound is identified early and treated appropriately has a dramatically better chance of survival, health maintenance, and eventual engagement with recovery services than one who loses a limb or develops sepsis from an unmanaged wound. Removing the organizations equipped to provide this care does not reduce drug use. It increases harm.

If you or someone you know needs help finding treatment, naloxone, or local harm reduction services that remain operating in your community, Rize Recovery can connect you with what’s available in Arizona and beyond. Start at rizerecovery.com/find-help.